Control of left ventricular mass by moxonidine involves reduced DNA synthesis and enhanced DNA fragmentation

British Journal of Pharmacology

Volumn 153, Issue 3, 2008, Pages 459-467

  Paquette, P A ^a,b   Duguay, D ^b   El Ayoubi, R ^a,b   Menaouar, A ^a,b   Danalache, B ^a,b   Gutkowska, J ^a,b   DeBlois, D ^b   Mukaddam Daher, S ^a,b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Apoptosis; DNA fragmentation; DNA synthesis; Hypertension; Left ventricular hypertrophy; Moxonidine

Indexed keywords

CASPASE 3; MOXONIDINE; PROTEIN BAX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BODY WEIGHT; DNA CONTENT; DNA FRAGMENTATION; DNA SYNTHESIS; DRUG EFFECT; ENZYME ACTIVATION; FLUID INTAKE; FOOD INTAKE; HEART LEFT VENTRICLE MASS; HEART RATE; MEAN ARTERIAL PRESSURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPONTANEOUSLY HYPERTENSIVE RAT; TELEMETRY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BCL-2-ASSOCIATED X PROTEIN; BLOOD PRESSURE; CASPASE 3; DISEASE MODELS, ANIMAL; DNA; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTROPHY, LEFT VENTRICULAR; IMIDAZOLES; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, INBRED SHR; TELEMETRY; TIME FACTORS;

EID: 38849117182     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707588     Document Type: Article

References (39)

1. Amador N, de Jesus Encarnacion J, Rodriguez L, Tello A, Lopez M, Guizar JM (2004). Relationship between left ventricular mass and heart sympathetic activity in male obese subjects. Arch Med Res 35: 411-415.
2. Amann K, Greber D, Gharehbaghi H, Wiest G, Lange B, Ganten U et al. (1992). Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats. Stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Am J Hypertens 5: 76-83.
3. Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A et al. (2000). Myocardial directed overexpression of the human beta(1)-adrenergic receptor in transgenic mice. J Mol Cell Cardiol 32: 817-830.
4. Bobik A, Dilley R, Kanellakis P (1998). Sympatho-adrenalmechanisms regulating cardiovascular hypertrophy in primary hypertension: a role for rilmenidine? J Hypertens 16: S51-S54.
5. Braz Nogueira J (2005). Regression of left ventricular hypertrophy in hypertension - does it reduce cardiovascular risk? Rev Port Cardiol 24: 1007-1013.
6. Briest W, Homagk L, Rassler B, Ziegelhoffer-Mihalovicova B, Meier H, Tannapfel A et al. (2004). Norepinephrine-induced changes in cardiac transforming growth factor-beta isoform expression pattern of female and male rats. Hypertension 44: 410-418.
7. Calderone A, Thaik CM, Takahashi N, Chang DL, Colucci WS (1998). Nitric oxide, atrial natriuretic peptide, and cyclic GMP inhibit the growth-promoting effects of norepinephrine in cardiac myocytes and fibroblasts. J Clin Invest 101: 812-818.
8. Der Sarkissian S, Marchand EL, Duguay D, Hamet P, deBlois D (2003). Reversal of interstitial fibroblast hyperplasia via apoptosis in hypertensive rat heart with valsartan or enalapril. Cardiovasc Res 57: 775-783.
9. El-Ayoubi R, Gutkowska J, Regunathan S, Mukaddam-Daher S (2002). Imidazoline receptors in the heart: characterization, distribution, and regulation. J Cadiovasc Pharmacol 39: 875-883.
10. 1-receptors and natriuretic peptides by chronic treatment with moxonidine. Ann N Y Acad Sci 1009: 274-278.
11. Engelhardt S, Hein L, Wiesmann F, Lohse MJ (1999). Progressive hypertrophy and heart failure in beta(1)-adrenergic receptor transgenic mice. Proc Natl Acad Sci USA 96: 7059-7064.
12. Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ et al. (2002). Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress. Circulation 105: 85-92.
13. Frey N, Katus HA, Olson EN, Hill JA (2004). Hypertrophy of the heart: a new therapeutic target? Circulation 109: 1580-1589.
14. Grassi G (2004). Counteracting the sympathetic nervous system in essential hypertension. Curr Opin Nephrol Hypertens 13: 513-519.
15. Greenwood JP, Scott EM, Stoker JB, Mary DA (2000). Chronic I(1)-imidazoline agonism: sympathetic mechanisms in hypertension. Hypertension 35: 1264-1269.
16. Hamet P, Richard L, Dam TV, Teiger E, Orlov SN, Gaboury L et al. (1995). Apoptosis in target organs of hypertension. Hypertension 26: 642-648.
17. Haxhiu MA, Dreshaj I, Schafer SG, Ernsberger P (1994). Selective antihypertensive action of moxonidine is mediated mainly by I1-imidazoline receptors in the rostral ventrolateral medulla. J Cardiovasc Pharmacol 24: S1-S8.
18. Ishimitsu T, Kobayashi T, Honda T, Takahashi M, Minami J, Ohta S et al. (2005). Protective effects of an angiotensin II receptor blocker and a long-acting calcium channel blocker against cardiovascular organ injuries in hypertensive patients. Hypertens Res 28: 351-359.
19. James TN (1998). Normal and abnormal consequences of apoptosis in the human heart. Annu Rev Physiol 60: 309-325.
20. Liao Y, Asakura M, Takashima S, Ogai A, Asano Y, Shintani Y et al. (2004). Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. Circulation 110: 692-699.
21. Mall G, Greber D, Gharenhbaghi H, Wiest G, Amann K, Mattfeldt T (1991). Effects of nifedipine and moxonidine on cardiac structure in spontaneously hypertensive rats (SHR) - stereological studies on myocytes, capillaries, arteries, and cardiac interstitium. Basic Res Cardiol 86 (Suppl 3): 33-44.
22. Masson S, Chimenti S, Salio M, Torri M, Limana F, Bernasconi R et al. (2001). CHF-1024, a DA2/alpha2 agonist, blunts norepinephrine excretion and cardiac fibrosis in pressure overload. Cardiovasc Drugs Ther 15: 131-138.
23. Menaouar A, El-Ayoubi R, Jankowski M, Gutkowska J, Mukaddam-Daher S (2002). Chronic imidazoline receptor activation in spontaneously hypertensive rats. Am J Hypertension 15: 803-808.
24. Messerli F (2000). Moxonidine: a new and versatile antihypertensive. J Cardiovasc Pharmacol 35 (7 Suppl 4): S53-S56.
25. Moreira TS, Takakura AC, Menani JV, Colombari E (2007). Involvement of central alpha1- and alpha2-adrenoceptors on cardiovascular responses to moxonidine. Eur J Pharmacol 563: 164-171.
26. Moreira TS, Takakura AC, Menani JV, Sato MA, Colombari E (2004). Central blockade of nitric oxide synthesis reduces moxonidine-induced hypotension. Br J Pharmacol 142: 765-771.
27. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, et al., (LIFE Study Investigators) (2004). Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292: 2343-2349.
28. Peng H, Carretero OA, Vuljaj N, Liao TD, Motivala A, Peterson EL et al. (2005). Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 112: 2436-2445.
29. Prichard BN (1994). Clinical experience with moxonidine. Cardiovasc Drugs Ther 8 (Suppl 1): 49-58.
30. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD (2003). Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565.
31. Singal T, Dhalla NS, Tappia PS (2004). Phospholipase C may be involved in norepinephrine-induced cardiac hypertrophy. Biochem Biophys Res Commun 320: 1015-1019.
32. Tea BS, Dam TV, Moreau P, Hamet P, deBlois D (1999). Apoptosis during regression of cardiac hypertrophy in spontaneously hypertensive rats: temporal regulation and spatial heterogeneity. Hypertension 34: 229-235.
33. Vakili BA, Okin PM, Devereux RB (2001). Prognostic implications of left ventricular hypertrophy. Am Heart J 141: 334-341.
34. Van Kerckhoven R, van Veghel R, Saxena PR, Schoemaker RG (2004). Pharmacological therapy can increase capillary density in post-infarction remodeled rat hearts. Cardiovasc Res 61: 620-629.
35. Varo N, Etayo JC, Zalba G, Beaumont J, Iraburu MJ, Montiel C et al. (1999). Losartan inhibits the post-transcriptional synthesis of collagen type I and reverses left ventricular fibrosis in spontaneously hypertensive rats. J Hypertens 17: 107-114.
36. Velliquette RA, Ernsberger P (2003). Contrasting metabolic effects of antihypertensive agents. J Pharmacol Exp Ther 307: 1104-1111.
37. Xu C, Bailly-Maitre B, Reed JC (2005). Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest 115: 2656-2664.
38. Yasunari K, Maeda K, Nakamura M, Watanabe T, Yoshikawa J, Hirohashi K (2005). Left ventricular hypertrophy and angiotensin II receptor blocking agents. Curr Med Chem Cardiovasc Hematol Agents 3: 61-67.
39. Ziegler D, Haxhiu MA, Kaan EC, Papp JG, Ernsberger P (1996). Pharmacology of moxonidine, an I1-imidazoline receptor agonist. J Cardiovasc Pharmacol 27 (Suppl 3): S26-S37.